Hawaii Biotech, Inc.

UEI
ECJKEEFL4L51
CAGE
0EAY9
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Website
hibiotech.com
Founded
1982
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

About Hawaii Biotech, Inc.

Hawaii Biotech, Inc. (HBI) is a biotechnology company focused on the research and development of prophylactic vaccines for infectious diseases. They are developing small molecule drug candidates for the treatment of Anthrax intoxication and botulism.

Through federal contracts, HBI has provided vaccine development services to the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID). In 2022, HBI was awarded a $2,997,218 firm fixed price contract under a total small business set aside to provide a Recombinant West Nile Virus Vaccine Adjuvanted with SLA-LSQ to NIAID. The contract runs through 2025 with performance taking place in Honolulu, Hawaii.

HBI has also received several federal grant awards from NIAID to fund vaccine research and development efforts. In 2023, they received a $611,830 Project Grant under CFDA 93.855 (Allergy and Infectious Diseases Research) to identify TLR-4 agonists with immunostimulatory properties suitable for development as vaccine adjuvants over a 2-year period. Activities include establishing synthesis routes, screening compounds, and evaluating immunogenic potency and safety compared to existing West Nile virus vaccines. Another 2023 NIAID Project Grant for $816,117 supports the development of a cross-protective New World Encephalitic Alphavirus subunit vaccine targeting Eastern, Venezuelan and Western Equine Encephalitis viruses in collaboration with Baylor College of Medicine over 2 years.

Quick answers

What is Hawaii Biotech, Inc.'s UEI?

Hawaii Biotech, Inc.'s Unique Entity ID (UEI) in SAM.gov is ECJKEEFL4L51.

What is Hawaii Biotech, Inc.'s CAGE code?

Hawaii Biotech, Inc.'s CAGE code is 0EAY9.

What is Hawaii Biotech, Inc.'s primary NAICS code?

Hawaii Biotech, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Is Hawaii Biotech, Inc. registered in SAM.gov?

Hawaii Biotech, Inc.'s SAM.gov registration expired on July 2, 2026.

What is Hawaii Biotech, Inc.'s most recent federal award?

Hawaii Biotech, Inc.'s most recent federal grant award is Novel TLR-4 agonists as vaccine adjuvants - abstract/project summary along with the many benefits of a global economy… (R43AI174478), from National Institute of Allergy and Infectious Diseases, on May 2, 2023.

On GovTribe

See Hawaii Biotech, Inc.'s full federal record

  • Federal contract awards
  • IDV awards
  • Federal grant awards
  • Subcontracting relationships
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors